298 related articles for article (PubMed ID: 24872311)
21. Type 2 diabetes and the polycystic ovary syndrome.
Pelusi B; Gambineri A; Pasquali R
Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
[TBL] [Abstract][Full Text] [Related]
22. Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
Mayer SB; Evans WS; Nestler JE
Womens Health (Lond); 2015 Mar; 11(2):137-49. PubMed ID: 25776288
[TBL] [Abstract][Full Text] [Related]
23. Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome.
Hutchison SK; Teede HJ; Rachoń D; Harrison CL; Strauss BJ; Stepto NK
Diabetologia; 2012 May; 55(5):1424-34. PubMed ID: 22246378
[TBL] [Abstract][Full Text] [Related]
24. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk in women with polycystic ovary syndrome.
Giallauria F; Orio F; Palomba S; Lombardi G; Colao A; Vigorito C
J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):987-92. PubMed ID: 18799960
[TBL] [Abstract][Full Text] [Related]
26. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
[TBL] [Abstract][Full Text] [Related]
27. Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.
Morrison SA; Goss AM; Azziz R; Raju DA; Gower BA
Hum Reprod; 2017 Jan; 32(1):185-192. PubMed ID: 27827322
[TBL] [Abstract][Full Text] [Related]
28. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome.
Mukherjee S; Maitra A
Indian J Med Res; 2010 Jun; 131():743-60. PubMed ID: 20571162
[TBL] [Abstract][Full Text] [Related]
29. The effectiveness of high intensity intermittent training on metabolic, reproductive and mental health in women with polycystic ovary syndrome: study protocol for the iHIT- randomised controlled trial.
Hiam D; Patten R; Gibson-Helm M; Moreno-Asso A; McIlvenna L; Levinger I; Harrison C; Moran LJ; Joham A; Parker A; Shorakae S; Simar D; Stepto N
Trials; 2019 Apr; 20(1):221. PubMed ID: 30992038
[TBL] [Abstract][Full Text] [Related]
30. Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: identification of susceptibility gene sets through network analysis.
Kaur S; Archer KJ; Devi MG; Kriplani A; Strauss JF; Singh R
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2016-21. PubMed ID: 22904171
[TBL] [Abstract][Full Text] [Related]
31. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
Nardo LG; Patchava S; Laing I
Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
[TBL] [Abstract][Full Text] [Related]
32. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus.
Dunaif A
Am J Med; 1995 Jan; 98(1A):33S-39S. PubMed ID: 7825639
[TBL] [Abstract][Full Text] [Related]
33. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
34. Polycystic ovarian syndrome.
Khan KA; Stas S; Kurukulasuriya LR
J Cardiometab Syndr; 2006; 1(2):125-30; quiz 131-2. PubMed ID: 17679815
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
36. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance.
Lambert EA; Teede H; Sari CI; Jona E; Shorakae S; Woodington K; Hemmes R; Eikelis N; Straznicky NE; De Courten B; Dixon JB; Schlaich MP; Lambert GW
Clin Endocrinol (Oxf); 2015 Dec; 83(6):812-9. PubMed ID: 25926334
[TBL] [Abstract][Full Text] [Related]
37. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
Baldani DP; Skrgatic L; Ougouag R; Kasum M
Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
[TBL] [Abstract][Full Text] [Related]
38. Insulin resistance and polycystic ovary syndrome.
Ehrmann DA
Curr Diab Rep; 2002 Feb; 2(1):71-6. PubMed ID: 12643125
[TBL] [Abstract][Full Text] [Related]
39. Conservative treatment options for polycystic ovary syndrome: the importance of exercise.
Líška D; Záhumenský J
Ceska Gynekol; 2020; 85(6):430-435. PubMed ID: 33711904
[TBL] [Abstract][Full Text] [Related]
40. Advanced glycation end products and their relevance in female reproduction.
Merhi Z
Hum Reprod; 2014 Jan; 29(1):135-45. PubMed ID: 24173721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
